Vaidya Sane Ayurved Laboratories Ltd
Incorporated in 2006, Vaidya Sane Ayurved Laboratories Ltd is the business of running
of hospitals & clinics, and sale of Ayurved based medicines[1]
- Market Cap ₹ 174 Cr.
- Current Price ₹ 166
- High / Low ₹ 178 / 81.1
- Stock P/E 30.2
- Book Value ₹ 56.8
- Dividend Yield 0.00 %
- ROCE 13.9 %
- ROE 10.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 3.06 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 3.15% over past five years.
- Company has a low return on equity of 8.25% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
62.30 | 74.61 | 52.01 | 74.24 | 99.03 | 97.33 | 87.11 | |
59.20 | 71.70 | 47.54 | 66.92 | 90.03 | 93.30 | 76.98 | |
Operating Profit | 3.10 | 2.91 | 4.47 | 7.32 | 9.00 | 4.03 | 10.13 |
OPM % | 4.98% | 3.90% | 8.59% | 9.86% | 9.09% | 4.14% | 11.63% |
0.07 | 0.07 | -1.06 | 0.34 | 1.36 | 1.56 | 0.57 | |
Interest | 0.70 | 1.20 | 0.51 | 0.63 | 0.85 | 1.11 | 0.10 |
Depreciation | 1.59 | 2.23 | 2.45 | 2.29 | 2.60 | 3.03 | 3.73 |
Profit before tax | 0.88 | -0.45 | 0.45 | 4.74 | 6.91 | 1.45 | 6.87 |
Tax % | 44.32% | 24.44% | 15.56% | 27.00% | 24.89% | 28.28% | 28.68% |
0.50 | -0.56 | 0.39 | 3.47 | 5.19 | 1.05 | 4.90 | |
EPS in Rs | 111.11 | -124.44 | 86.67 | 3.30 | 4.94 | 1.00 | 4.66 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 5.06% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 3% |
3 Years: | 5% |
TTM: | -11% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 65% |
3 Years: | 18% |
TTM: | 540% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -2% |
1 Year: | 12% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | 8% |
Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0.05 | 0.05 | 0.05 | 10.51 | 10.51 | 10.51 | 10.51 |
Reserves | 8.74 | 8.17 | 9.72 | 25.37 | 30.30 | 44.51 | 49.19 |
8.67 | 5.97 | 1.02 | 1.06 | 0.13 | 1.68 | 1.46 | |
11.41 | 14.93 | 15.02 | 13.07 | 14.34 | 14.70 | 12.67 | |
Total Liabilities | 28.87 | 29.12 | 25.81 | 50.01 | 55.28 | 71.40 | 73.83 |
15.66 | 15.51 | 17.16 | 17.01 | 20.95 | 22.08 | 28.23 | |
CWIP | 2.02 | 3.79 | 0.38 | 1.23 | 1.67 | 2.60 | 0.00 |
Investments | 0.02 | 0.02 | 0.01 | 21.49 | 14.85 | 11.11 | 26.38 |
11.17 | 9.80 | 8.26 | 10.28 | 17.81 | 35.61 | 19.22 | |
Total Assets | 28.87 | 29.12 | 25.81 | 50.01 | 55.28 | 71.40 | 73.83 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
1.58 | 7.72 | 5.77 | -13.31 | -0.43 | -3.11 | 7.58 | |
-10.05 | -3.93 | -0.67 | -7.52 | 1.00 | 0.02 | -6.91 | |
7.71 | -3.63 | -5.26 | 22.49 | -1.38 | 14.46 | -0.54 | |
Net Cash Flow | -0.77 | 0.16 | -0.16 | 1.66 | -0.81 | 11.37 | 0.14 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|
Debtor Days | 21.38 | 12.23 | 18.53 | 17.50 | 23.81 | 27.86 | 29.46 |
Inventory Days | 76.92 | 49.49 | 35.00 | 31.08 | |||
Days Payable | 137.65 | 138.39 | 146.74 | 111.56 | |||
Cash Conversion Cycle | -39.34 | -76.67 | -93.21 | 17.50 | 23.81 | 27.86 | -51.02 |
Working Capital Days | -7.15 | -26.07 | -46.39 | -25.27 | 1.99 | 2.55 | 56.73 |
ROCE % | 4.74% | 16.97% | 22.50% | 19.93% | 4.81% | 13.86% |
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
27 May 2025 - FY25 earnings call: Rs 89.85 Cr revenue, Rs 7.15 Cr PAT, cost cuts, new clinics and hospital expansions planned.
-
General Updates
24 May 2025 - Published audited standalone and consolidated financial results for FY ended March 31, 2025.
-
Analysts/Institutional Investor Meet/Con. Call Updates
23 May 2025 - Audio recording of FY25 earnings conference call submitted and available on company website.
-
Investor Presentation
23 May 2025 - Investor presentation on audited FY25 financial results and company overview for Vaidya Sane Ayurved Laboratories.
-
Outcome of Board Meeting
22 May 2025 - Audited financial results for FY 2024-25 approved; unmodified audit opinion; internal controls effective.
Annual reports
Concalls
-
May 2025Transcript PPT
-
Nov 2024TranscriptPPT
-
Jun 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Nov 2023Transcript PPT REC
-
Nov 2023Transcript PPT
-
May 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
Business Overview:[1][2][3]
VSALL is a chain of Cardiac Care Clinics and hospitals that have 350+ Clinics, out of these 54 are company-owned, 62 are OPD’s Mini Clinic and 234 are franchised clinics. These are run by 450+ Ayurvedic Physicians. Company also has 2 hospitals viz. Madhavbaug Hospital, Khopoli (NABH Accredited) and Madhavbaug Hospital Nagpur.